文献速递泌尿生殖与妇科肿瘤放疗

前列腺癌中度与超大分割放疗后急性毒性模式及其管理:一项前瞻性队列研究

Acute toxicity patterns and their management after moderate and ultra- hypofractionated radiotherapy for prostate cancer: A prospective cohort study.
PubMed 文献 · Clin Transl Radiat Oncol · 2024-08-17

该前瞻性队列纳入316例前列腺癌患者,分别接受中度大分割(MHF,20次3/3.1 Gy,每周5次,156例)或超大分割(UHF,7次6.1 Gy,每周3次,160例)放疗。结果显示UHF在选定人群中急性毒性风险安全,MHF与显著腹泻风险相关且需进一步研究,UHF急性毒性最佳登记需在末次分割后1-2周内测量。

要点

  • 急性泌尿症状治疗处方率MHF为46%、UHF为29%,考虑基线下尿路症状后两组患者报告结局与管理率相似。
  • 急性胃肠道症状药物处方率MHF为21.1%、UHF为14.1%,MHF腹泻用洛哌丁胺更多(9.0% vs 1.9%,p=0.005)。
  • ≥2级胃肠道毒性MHF为40%、UHF为28%(p=0.03);≥2级泌尿生殖毒性MHF为50%、UHF为31%(p<0.01)。

核心结论

  • UHF在选定人群中就急性毒性风险而言是安全的。
  • MHF与显著腹泻风险相关,需进一步研究。
  • UHF急性毒性最佳登记需在末次分割后1-2周内测量。

研究设计与样本

  • 前瞻性队列研究,纳入316例前列腺癌患者,于2019年至2023年接受前列腺±(基底部)精囊放疗。
  • MHF组156例接受20次3/3.1 Gy、每周5次;UHF组160例接受7次6.1 Gy、每周3次。
  • 存在显著下尿路症状或T3b疾病时不予UHF。
  • 患者报告结局通过在线方式在基线、治疗结束时(目标为末次分割±3天)及3个月时发放。
  • 采用卡方检验和逻辑回归分析急性毒性发生率、管理及与基线因素的关联,并计算CTCAE第5版评分。

主要发现

  • 急性泌尿症状治疗处方率MHF为46%、UHF为29%。
  • 考虑基线下尿路症状后,MHF与UHF的患者报告结局和管理率相似。
  • 急性胃肠道症状药物处方率MHF为21.1%、UHF为14.1%,MHF腹泻用洛哌丁胺更多(9.0% vs 1.9%,p=0.005)。
  • ≥2级胃肠道毒性MHF为40%、UHF为28%(p=0.03);≥2级泌尿生殖毒性MHF为50%、UHF为31%(p<0.01)。
  • UHF末次分割后报告的胃肠道患者报告结局较末次分割前显著更差。

局限性

  • MHF与显著腹泻风险相关,需进一步研究。
  • UHF急性毒性最佳登记需在末次分割后1-2周内测量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Hypofractionation has become the new clinical standard for prostate cancer. We investigated the management of acute toxicity in patients treated with moderate hypofractionation (MHF) or Ultrahypofractionation (UHF). METHODS: In a prospective cohort setting, patients (N=316) received either MHF (20 fractions of 3/3.1 Gy, 5 fractions per week, N=156) or UHF (7 fractions of 6.1 Gy, 3 fractions per week, N=160) to the prostate +/- (base of the) seminal vesicles between 2019 and 2023. UHF was not indicated in case of significant lower urinary tract symptoms (LUTS) or T3b disease. Patient-reported outcomes (PRO) were online distributed at baseline, end of treatment (aiming at last fraction +/- 3 days), 3 months. Acute toxicity rates, management, and associations with baseline factors were analysed using Chi-square test and logistic regression. CTCAE scores (version 5) were calculated. RESULTS: Treatment for acute urinary complaints was prescribed in 46 % (MHF) and 29 % (UHF). Taking into consideration baseline LUTS, MHF and UHF showed similar rates of PROs and management. Medication for acute gastrointestinal (GI) symptoms was prescribed for 21.1 % (MHF) and 14.1 % (UHF) with more loperamide for diarrhea in MHF (9.0 %) vs UHF (1.9 %, p = 0.005). Grade ≥ 2 (MHF / UHF) was scored in 40 % / 28 % for GI (p = 0.03) and 50 % / 31 % for GU (p < 0.01). PROs for GI reported after last fraction of UHF were significantly worse compared to before last fraction. CONCLUSION: UHF was safe with respect to acute toxicity risks in the selected population. MHF is associated with risks of significant diarrhea which needs further investigation. Furthermore, optimal registration of acute toxicity for UHF requires measurements up to 1-2 weeks after the last fraction.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Sinzabakira F, Incrocci L, de Vries K, et al. Acute toxicity patterns and their management after moderate and ultra- hypofractionated radiotherapy for prostate cancer: A prospective cohort study. Clin Transl Radiat Oncol. 2024. PMID: 39262841. doi:10.1016/j.ctro.2024.100842

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。